Royce & Associates LP grew its holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 2.2% in the third quarter, HoldingsChannel reports. The institutional investor owned 1,599,700 shares of the medical instruments supplier’s stock after acquiring an additional 34,700 shares during the period. Royce & Associates LP’s holdings in Harvard Bioscience were worth $8,398,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. First Light Asset Management LLC boosted its stake in shares of Harvard Bioscience by 9.4% during the 2nd quarter. First Light Asset Management LLC now owns 5,951,014 shares of the medical instruments supplier’s stock worth $31,838,000 after purchasing an additional 509,724 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Harvard Bioscience by 3.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,937,940 shares of the medical instruments supplier’s stock worth $10,368,000 after purchasing an additional 70,805 shares during the period. Rhumbline Advisers purchased a new position in shares of Harvard Bioscience during the 2nd quarter worth about $164,000. Granahan Investment Management Inc. MA boosted its stake in shares of Harvard Bioscience by 11.8% during the 2nd quarter. Granahan Investment Management Inc. MA now owns 1,075,363 shares of the medical instruments supplier’s stock worth $5,753,000 after purchasing an additional 113,716 shares during the period. Finally, BlackRock Inc. boosted its stake in shares of Harvard Bioscience by 105.3% during the 2nd quarter. BlackRock Inc. now owns 2,934,267 shares of the medical instruments supplier’s stock worth $15,699,000 after purchasing an additional 1,504,668 shares during the period. 74.27% of the stock is owned by institutional investors and hedge funds.
A number of research firms recently commented on HBIO. Zacks Investment Research cut shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a research note on Wednesday, September 26th. ValuEngine lowered shares of Harvard Bioscience from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 22nd.
Shares of HBIO opened at $3.54 on Friday. Harvard Bioscience, Inc. has a 1-year low of $3.05 and a 1-year high of $6.70. The stock has a market cap of $138.73 million, a P/E ratio of 31.00 and a beta of 1.30. The company has a debt-to-equity ratio of 0.73, a current ratio of 2.83 and a quick ratio of 1.49.
Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings data on Thursday, October 25th. The medical instruments supplier reported $0.04 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.04. Harvard Bioscience had a negative net margin of 4.18% and a positive return on equity of 5.54%. The company had revenue of $28.71 million during the quarter, compared to analyst estimates of $28.50 million. Research analysts forecast that Harvard Bioscience, Inc. will post 0.12 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Royce & Associates LP Acquires 34,700 Shares of Harvard Bioscience, Inc. (HBIO)” was first published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2018/12/08/royce-associates-lp-acquires-34700-shares-of-harvard-bioscience-inc-hbio.html.
About Harvard Bioscience
Harvard Bioscience, Inc develops, manufactures, and markets scientific instruments, systems, and lab consumables used in life science basic research, drug discovery, and clinical and environmental testing. The company offers physiology, cell, and molecular instruments, such as traditional syringe pump and peristaltic pump products, as well as a range of instruments and accessories for tissue, organ, and animal based lab research under the Harvard Apparatus, CMA Microdialysis, Panlab, Coulbourn, and Hugo Sachs brands; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation instruments that are marketed under the Biochrom, Libra, WPA, BioDrop, Hoefer, Scie-plas, and BTX brand names.
Recommended Story: Book Value Per Share in Stock Trading
Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO).
Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.